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Elevated circulating amyloid concentrations in obesity and diabetes 
promote vascular dysfunction.  
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Diabetes, obesity and Alzheimer’s disease (AD) are associated with vascular complications 
and impaired nitric oxide (NO) production. Furthermore, increased b-site amyloid precursor 
protein (APP)-cleaving enzyme 1 (BACE1), APP and b-amyloid (Ab) are linked with vascular 
disease development and raised BACE1 and Ab accompany hyperglycemia and 
hyperlipidemia. However, the causal relationship between obesity and diabetes, raised Ab and 
vascular dysfunction is unclear. We report that diet-induced obesity (DIO) in mice raised 
plasma and vascular Ab42 that correlated with decreased NO bioavailability, endothelial 
dysfunction and raised blood pressure.  Genetic or pharmacological reduction of BACE1 
activity and Ab42 prevented and reversed, respectively, these outcomes. In contrast, 
expression of human mutant APP in mice or Ab42 infusion into control diet-fed mice to mimic 
obese levels impaired NO production, vascular relaxation and raised blood pressure. In 
humans, raised plasma Ab42 correlated with diabetes and endothelial dysfunction. 
Mechanistically, higher Ab42 reduced endothelial NO synthase (eNOS), cyclic GMP and 
protein kinase G (PKG) activity independently of diet whereas endothelin-1 was increased by 
diet and Ab42. Lowering Ab42 reversed the DIO deficit in the eNOS-cGMP-PKG pathway and 
decreased endothelin-1. Our findings suggest that BACE1 inhibitors may have therapeutic 
value in the treatment of vascular disease associated with diabetes. 
 
 
  
  3 
Introduction  
There is increasing evidence that links vascular disease and endothelial dysfunction (as found 
in obesity, diabetes and hypercholesterolemia; i.e. metabolic syndrome) with Alzheimer’s 
disease (AD) and cognitive impairment, through many shared risk factors (1). Indeed, 
cognitive decline and AD are associated with cerebrovascular and coronary atherosclerosis 
in humans and people with AD exhibit pathological signs of vascular impairment in cerebral 
and peripheral vessels, indicating some commonality between peripheral and central disease 
mechanisms (2). Moreover, vascular dysfunction occurs early in AD progression, often 
reported decades before the development of clinical symptoms of dementia (3). Recent work 
has demonstrated an interesting connection between one of the early biochemical events 
associated with AD and cerebral blood vessel dysfunction. The proteolytic cleavage of amyloid 
precursor protein (APP) by the enzyme, b-site APP-cleaving enzyme 1 (BACE1) is the rate 
limiting step and one of the main drivers for production of b-amyloid (Ab) peptides.  Excessive 
accumulation of Ab results in aggregation into amyloid plaques, a hallmark pathology of AD. 
Increased protein expression of APP, BACE1 and raised levels of Ab peptides (Ab40 and Ab42) 
have been demonstrated in cerebral blood vessels in humans with AD and are detectable in 
experimental models of AD prior to the appearance of AD pathology and cognitive decline (4-
7). Therefore, increased APP processing and Ab production may be directly linked to 
endothelial dysfunction in cerebral and peripheral blood vessels. However, the role of APP 
processing and Ab production in endothelial dysfunction in obesity and diabetes is not clear. 
 
Endothelial dysfunction is frequently observed in experimental models of diabetes (8,9) and is 
characterised, in part, by impaired nitric oxide (NO) mediated relaxation. Furthermore, 
diabetes is commonly associated with microvascular and macrovascular complications, 
including ischemic heart disease, peripheral vascular disease, atherosclerosis and congestive 
heart failure, accounting for up to 80% of the excess mortality in patients with diabetes (10). 
In a clinical setting endothelial dysfunction, impaired early in diabetes development, is strongly 
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associated with adverse outcomes (11) and contributes to the development of insulin 
resistance, microangiopathy (12) and atherosclerosis (13). Importantly impaired endothelium-
dependent vasodilation is measurable before any morphological changes are detected in the 
vessel wall (14) indicating that reduced NO production and/or activity may be an important 
early event in vascular pathogenesis. 
 
Aβ peptides at high concentrations are toxic to brain and peripheral endothelial cells, causing 
cellular damage, enhanced vasoconstriction and impairment of endothelium-dependent 
relaxation, thereby promoting atherosclerosis and vascular disease (15). These actions are 
associated with reduced glucose delivery, increased hypoxia and oxidative stress in the 
neurovascular unit and are significant contributors to the pathology that defines 
neurodegeneration and AD. In addition, APP and Aβ are detected in human carotid plaques 
and atherosclerotic aortas (16), and overexpression of APP accelerates (17), whereas deletion 
partially protects against, (18) the development of aortic atherosclerosis in APOE-/- mice.  Ex 
vivo and in vitro studies have demonstrated that soluble Ab peptides reduce endothelial NO 
production, potentially by inhibition of eNOS phosphorylation at Ser1177 (19,20). However, 
these studies used excessively high (~1µM) concentrations of Ab peptides, whereas reported 
in vivo levels are significantly lower (21,22) and vary between ~5–800 pg/ml (~1–200 pM) for 
Ab42 and 35–700 pg/ml for Ab40 (~9–180 pM) in plasma. Interestingly, eNOS modulates 
amyloid processing, as reduction or loss of eNOS is associated with increased expression of 
APP and BACE1 and the production of Aβ peptides whereas exogenous NO reduces APP, 
BACE1 and Aβ levels in cerebral microvessels (23). Thus, there appears to be an interesting 
reciprocal connection between BACE1, APP processing, Ab levels and NO bioavailability.  
Hyperglycemia and hyperlipidemia increase BACE1 activity and Ab peptide levels in tissues 
and plasma (24,25), linking key metabolic disease markers with increased amyloid 
processing. Consequently, we hypothesised that the development of T2D and/or obesity 
elevates circulating Aβ levels which in turn drives vascular dysfunction. We tested this 
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hypothesis in three ways: firstly, by reducing BACE1 activity genetically and pharmacologically 
in mice and ascertaining how this modified diet-induced endothelial dysfunction; secondly by 
increasing plasma Ab levels, indirectly through over-expression of mutant human APP genes 
and directly by Ab peptide infusion, to promote vascular dysfunction in mice; thirdly by 
examining cross-sectionally the association between plasma Ab levels and endothelial 
function in patients with T2D.  
  6 
Results 
BACE1 expression and activity in the vasculature. 
BACE1 protein was detected in vascular tissue (aorta) from regular chow (RC)-fed wild type 
(WT) mice, with expression increased (Figure 1A) in mice made obese by high fat (HF) diet 
for 20 weeks (diet-induced obese (DIO) mice; Table 1, Supplemental Figure 1A)). BACE1 
protein was localised (Figure 1B) to endothelial and vascular smooth muscle cells (VSMC).  
BACE1 protein expression was detectable in control (non-obese/diabetic) human temporal 
arteries (Figure 1C) and the expression of BACE1 mRNA in human internal mammary artery 
was higher in obese (BMI ≥ 35 kg/m2), compared to lean individuals (Figure 1D), although no 
difference in BACE1 mRNA expression was observed when correlated with insulin resistance 
or diabetes (Supplemental Figure 2, Supplemental Table1).  BACE1 activity (measured by 
sAPPb levels) in the aorta of DIO mice was increased compared to age-matched RC-fed 
controls or BACE1 knock-out (BACE1KO) mice on either diet (Figure 1E, main effect of diet, 
P<0.05), with a corresponding increase in DIO mouse aorta of the sequential g-secretase 
cleavage product, Ab42 (Figure 1F, diet x genotype, P<0.001).  Levels of sAPPb and Ab42 
levels were barely detectable in the aortas of BACE1KO mice, on either RC- or HF-diet (Figure 
1, E and F).  
 
Ab40 and Ab42 plasma levels in mice and humans. 
Plasma levels of Ab42 were raised in DIO mice in comparison to age-matched RC-fed controls, 
to levels that were not significantly different to that obtained in RC-fed AD transgenic mice 
expressing human APP with the Swedish mutation (hAPPSw) mice, with BACE1KO mice 
displaying very low plasma Ab42 levels (Figure 1G, diet x genotype, P<0.01).  Plasma Ab40 
levels were also reduced in BACE1KO mice compared to age-matched RC-fed and DIO mice, 
however plasma Ab40 levels in WT mice are not sensitive to the HF diet (Figure 1H, main effect 
of genotype, P<0.001). In agreement with the results for DIO mice, we find that human plasma 
Ab42, but not Ab40, levels (Human Study 1), are raised (Figure 1I) in T2D patients (n = 20) 
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versus a control (n = 20) group (matched for age (61.2 ± 12.5 and 67.2 ± 10.4 years, 
respectively) and gender (male:female = 9:11 and 8:12, respectively)) and show a significant 
linear relationship with glycated hemoglobin (HbA1c: Figure 1J), with mean values for HbA1c 
of 63.8  ± 4.2 and 38.0 ± 0.7 (P=0.0001), respectively. Body mass index was greater in patients 
with T2D (32.3 ± 1.7 and 26.7 ± 0.9 kg/m2 (P=0.007)). There was no relationship between Ab42 
levels and age in this cohort, tested by linear regression (r2=0.014, P=0.31).  
 
Genetic reduction of BACE1 protects against HF diet-induced vascular dysfunction. 
The role of BACE1 activity on endothelium-dependent and independent vascular responses 
was examined in the microvasculature of RC-fed WT, DIO and RC- and HF-fed BACE1KO 
mice. We also measured body weight, fasted blood glucose, glucose and insulin sensitivity in 
the mice as these parameters are sensitive to BACE1 levels and activity (26,27).  DIO mice, 
which developed obesity with hyperglycemia and insulin resistance (Supplemental Figure 1 
B-D, Table 1) showed impaired endothelium-dependent vasodilation induced by iontophoresis 
of acetylcholine (ACh) (Figure 2, A and B) and endothelium-independent vasodilation by 
iontophoresis of the NO donor sodium nitroprusside (SNP) (Figure 2, C and D), compared to 
RC-fed WT mice. In contrast, BACE1KO mice (RC- or HF-fed) displayed no impairment in 
endothelium-dependent (Figure 2, A and B, diet x genotype, P<0.01) or endothelium-
independent vasodilation by diet (Figure 2, C and D, diet x genotype, P<0.001). To establish 
the relative role of endothelium-derived NO in the ACh-mediated vascular responses, mice 
were pre-treated with the NO synthase inhibitor N (G)-nitro-L-arginine methyl ester 
hydrochloride (L-NAME). Administration of L-NAME blunted vascular responses to ACh in RC-
fed WT, DIO and RC- and HF-fed BACE1KO mice (Figure 2, E and F, main effect of diet, 
P<0.001) demonstrating that a major proportion of the ACh-induced vascular response is NO-
dependent in both WT and BACE1KO mice. Thus, in contrast to WT mice, BACE1KO mice retain 
normal NO mediated vasodilation after chronic HF feeding.  
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To determine the contribution of BACE1 activity and dietary challenge on the maximum 
dilatory capacity of the vasculature, the response to localised heating was determined (Figure 
2, G and H). Although DIO mice displayed a significantly impaired vasodilator response to 
heat compared to RC-fed WT mice, RC-and HF-fed BACE1KO mice exhibited a maximal 
vasodilator response to heating that was comparable to WT mice fed a RC diet (diet x 
genotype, P<0.001).  Collectively, these results clearly implicate BACE1 activity in the control 
of endothelium-dependent and endothelium-independent vascular relaxation of HF-fed mice 
in response to ACh, SNP and raised skin temperature. 
 
Enhanced amyloidogenic processing impairs vascular function in RC-fed mice. 
The primary substrate identified for BACE1 is APP, with HF-feeding increasing BACE1 activity 
and enhancing APP cleavage raising Ab peptide levels (28).  We find that chronic HF-feeding 
leading to obesity increases Ab42, but not Ab40 levels in plasma (Figure 1, G and H).  To 
address further the role of Ab42 in vascular dysfunction, we infused WT mice with a 
physiological dose of mouse Ab42, or equivalent dose of scrambled peptide (ScrP) as control, 
either early in the HF feeding regime (infusion begun after 1 week of HF diet), at a stage when 
vascular dysfunction is not evident (Supplemental Figure 3) and plasma Ab42 levels remain 
low, or at an equivalent age in mice maintained on RC diet. Total mean Ab42 plasma levels in 
the Ab42, but not ScrP, infused 5-week HF- or RC-fed mice, reached quantities comparable to 
that obtained for DIO mice (i.e. after 20 weeks HF-feeding) (Figure 3A and Figure 1G). The 
elevated plasma Ab42 caused impaired ACh-induced vasodilation, in contrast to the ScrP-
treated mice, which retained normal responses to ACh (Figure 3B). Similarly, the presence of 
raised plasma Ab42 impaired SNP-mediated vasodilation, compared to ScrP-treated mice in 
5-week HF-fed mice (Figure 3C). These data led us to examine whether raised physiological 
or pathophysiological levels of Ab42 were the primary driver for the compromised vascular 
responses associated with the HF diet.  
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Consequently, we utilised two models where circulating Aβ42 levels are raised, independently 
of HF diet. Firstly, vascular responses were measured in hAPPSw mice (29) on RC diet. 
Overexpression of the hAPPSw form in these mice significantly increased total plasma Ab42 
levels (Figure 1G) to levels comparable to DIO mice. The elevated plasma Aβ42 impaired ACh 
induced vasodilation in the hAPPSw mice, which was further reduced in the presence of L-
NAME by a similar amount compared with responses for WT RC-fed mice (80% vs 65% 
reduction) demonstrating that the ACh response, although diminished, remained 
predominantly NO dependent (Figure 3D). Furthermore, the SNP induced vasodilation was 
also impaired in hAPPSw mice indicating enhanced Aβ production also results in the 
development of VSMC dysfunction (Figure 3E).   Next, we infused Aβ42 or ScrP into WT mice 
maintained on RC diet for 28 days (Figure 3A). This increased plasma Aβ42 had no effect on 
body weight or fasted blood glucose levels (Table 2) but reduced vascular responses to ACh 
(Figure 3F) and SNP (Figure 3G), indicating that raised plasma Aβ42 is responsible for the 
inhibition of NO-mediated vasodilation, independent of dietary influence. 
 
BACE1 inhibition reverses vascular dysfunction. 
We subsequently examined whether reduction of the elevated Aβ42 levels by pharmacological 
intervention might be a potential means to reverse vascular dysfunction. First, a 4-week 
infusion of the BACE1 inhibitor M-3 reduced plasma Aβ42 levels (Figure 4A) and significantly 
improved ACh induced vasodilation in DIO mice, with responses recovered to values similar 
to RC-fed WT mice (dashed line; Figure 4B).  In addition, endothelium-independent (SNP) 
vasodilator responses were improved by the infusion of M-3 in DIO mice, although the mean 
response amplitude was lower than WT RC-fed mice (dashed line; Figure 4C). The treatment 
of DIO mice with M-3 also reduced their fasted blood glucose levels and lowered body weight 
(Table 2), as reported previously (30). Next, the effects of BACE1 inhibitor infusion were 
examined on a mouse model overexpressing human APP, the hAPP23 mouse (31), which 
has higher expression of APP than hAPPSw, and exhibits early cognitive impairment and 
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extensive b-amyloid pathology (at 3-6 months) (32).  hAPP23 mice at 4 months age, like 
hAPPSw, displayed impaired vasodilation responses to ACh and SNP and these responses 
were significantly improved by the presence of M-3 (Supplemental Figure 4, A and B).  
 
Taken together these data demonstrate that pathophysiological levels (>20 pg/ml) of plasma 
Ab42 impair vascular responses independently of the presence of obesity and/or diabetes. 
Furthermore, as HF feeding preferentially promotes Aβ42 production, the raised level of this 
amyloid peptide species may be the mechanism by which obesity results in vascular 
dysfunction. This is further highlighted when the magnitude of the ACh (Figure 4D) or SNP 
(Figure 4E) induced vasodilation responses for the experimental protocols reported here, is 
plotted against plasma Aβ42 levels, giving inverse relationships, illustrating that decreased 
ACh and SNP responsiveness correlates with higher plasma Aβ42 levels. Consequently, 
targeting increased BACE1 activity to reduce the raised Aβ42 levels found in obesity- and 
diabetes-driven vascular disease, may recover vascular function. 
 
Ab42 suppresses NOx while enhancing ET-1 production.   
Excessive endothelin-1 production coupled with reduced NO levels results in a critical 
imbalance between these two potent vaso-modulators and subsequently promotes vascular 
dysfunction. Accordingly, we set out to determine whether the raised levels of Aβ42 associated 
with our mouse models alters the amounts of NO and ET-1 and contributes to this outcome. 
Therefore, first we determined whether decreased bio-availability of NO aids the suppression 
of vasodilation in mice with raised plasma Ab42. We found that the levels of total plasma NO 
(NOx) were diminished in WT mice by HF-feeding, whereas NOx levels were unchanged in 
BACE1KO mice on RC or HF diets (Figure 5A, diet x genotype, P<0.01).  NOx was also found 
to be suppressed in hAPPSw (Figure 5A) and hAPP23 mice (Supplemental Figure 4C) on RC 
diet.  Furthermore, RC-fed and short-term (5 weeks) HF-fed WT mice infused with Aβ42 (versus 
ScrP controls) also exhibited reduced NOx levels (Figure 5B, main effect of treatment, P<0.01), 
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whereas DIO mice given the BACE1 inhibitor M-3 displayed increased NOx levels (Figure 5C). 
hAPP23 mice given M-3 also showed a trend for increased NOx (Supplemental Figure 4C).  
In contrast, plasma ET-1 levels were raised in DIO mice compared to age-matched mice on 
RC diet, an outcome not observed in HF-fed BACE1KO mice, which displayed values identical 
to RC-fed WT and BACE1KO mice (Figure 5D, diet x genotype, P<0.01). Additionally, raised 
ET-1 levels were not observed in RC-fed hAPPSw (Figure 5D) or hAPP23 (Supplemental 
Figure 4D) mice.  Interestingly, ET-1 plasma levels were not altered in RC-fed WT mice 
infused with Ab42 (versus ScrP controls), although short-term HF-fed mice given Ab42 exhibit 
increased ET-1 compared to ScrP-infused controls (Figure 5E, diet x treatment, P<0.05). The 
elevated endothelin-1 levels in DIO mice were lowered by M-3 (Figure 5F) and baseline ET-1 
levels decreased in hAPP23 mice given M-3 (Supplemental Figure 4D). These outcomes 
demonstrate that long-term HF-feeding reduces the bioavailability of plasma NOx and raises 
plasma ET-1 levels.  However, although elevation of plasma Aβ42 levels to that of DIO mice in 
RC-fed and short-term HF-fed WT mice reproduced the decline in plasma NOx, ET-1 levels 
were unaffected by Aβ42 per se and appear to be up-regulated primarily by HF diet, with Ab42 
playing a permissive role.   
 
Aortic vessel lipid deposition and structure. 
Endothelial dysfunction is present in the early, preclinical, stage of atherosclerosis (13) and 
raised Ab promotes atherosclerosis, inflammation and vascular pathology (15-17). As 
diabetes and obesity are major risk factors for atherosclerosis, we examined whether there 
were indications of aortic vessel lipid deposition, inflammation or structural alterations 
associated with the endothelial functional changes observed in these mouse models.  Oil red 
O staining of aortic arches from RC- or HF-fed (5 and 12 weeks of HF diet) WT and BACE1KO 
mice and WT mice infused with Ab42 or ScrP for 28 days (5 weeks HF diet) exhibited no 
detectable lipid deposition (Supplemental Figure 5A-D). In addition, immunohistological 
analysis of peri-renal aortic sections using Isolectin B4 as a marker for endothelial cells and 
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macrophages, of RC- and HF-fed (12 weeks HF diet) WT and BACE1KO and WT mice infused 
with Ab42 or ScrP for 28 days (5 weeks HF diet) showed no macrophage infiltration or loss of 
endothelial cells (Supplemental Figure 6A-C), with unchanged aortic wall thickness 
(Supplemental Figure 6D). 
 
Ab42 production regulates NO signalling. 
Next, we explored the potential mechanism(s) by which raised BACE1 activity and higher 
plasma Ab42 act to regulate NO mediated vasodilation. Vasodilation induced by NO is 
dependent upon augmented production of cGMP and the subsequent activation of PKG in the 
vascular smooth muscle, leading to relaxation. Furthermore, increased levels of plasma Ab42 
diminished vascular responses to the NO donor SNP, indicating Ab42 alters VSMC signalling 
in response to NO.  Consequently, we measured aortic cGMP and demonstrated that cGMP 
levels were lower in DIO mice (versus RC-fed controls) and in RC-fed hAPPSw mice, but not 
in RC- or HF-fed BACE1KO mice (Figure 5G, diet x genotype, P<0.01).  In addition, RC- and 
HF-fed WT mice infused with Aβ42 exhibited diminished aortic cGMP levels (Figure 5H, diet x 
treatment, P<0.01), whereas DIO mice given the BACE1 inhibitor showed recovery of aortic 
cGMP levels (Figure 5I). In vascular endothelial cells, eNOS uses l-arginine to produce NO, 
which maintains blood flow and reduces inflammation. Reduced availability of l-arginine to 
eNOS and the resultant reduction of NO production has been implicated in the vascular 
dysfunction associated with diabetes, other cardiovascular disease states and AD (33,34). 
Therefore, we examined eNOS and p-eNOS (at Ser1177) levels, the latter as a surrogate 
measure of eNOS activity, in aortas by immunoblot.  DIO mice displayed reduced p-eNOS 
levels (with no change in total eNOS) compared to RC-fed controls, whereas HF-fed BACE1KO 
mice exhibited raised p-eNOS compared to DIO mice (Figure 6A and B). Increased plasma 
Ab42 levels, associated with hAPPSw mice or Ab42 infusion into short-term HF- or RC-fed mice 
resulted in reduced p-eNOS levels in aorta (Figure 6A and B and Figure 7, A and B). In contrast, 
DIO mice given a BACE1 inhibitor displayed increased aortic p-eNOS levels (Figure 7A and 
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B).  Consequently, these data support the notion that Aβ inhibits NO production via 
suppression of eNOS activity.  
 
The key enzymes involved in the phosphorylation and subsequent activation of eNOS in 
vascular endothelium are PKB and AMPK. Ab has been shown to down-regulate PKB 
expression and activity in skeletal muscle and brain; while suppressed AMPK activity has been 
implicated in AD pathogenesis (35). In general agreement with these findings, HF-fed mice 
with very low levels of Ab42 (BACE1KO mice) displayed enhanced p-PKB and p-AMPK levels 
versus DIO mice (Figure 6A and B). Raised levels of Aβ42 were associated with reduced p-
PKB(Ser473) in RC- or HF-fed mice and RC-fed hAPPSw mice, with p-AMPK(Thr172) levels 
significantly reduced in RC- and HF-fed WT mice (Figure 6A and B and Figure 7, A and B).  
However, DIO mice given the BACE1 inhibitor demonstrate increased p-PKB and p-AMPK 
levels (Figure 7A and B).  Collectively these results indicate that depression of Ab42 levels in 
DIO mice leads to enhanced PKB and AMPK activity, increased eNOS phosphorylation and 
production of NO, while raised Aβ42 tends to suppress PKB activity predominantly, correlating 
with reduced eNOS phosphorylation and NO levels. The enhanced levels of Ab42 also resulted 
in diminished vascular responses to the NO donor SNP and depressed cGMP, indicating that 
Aβ42 may directly alter VSMC signalling in response to NO. Indeed, we found that total PKG 
levels and activity, the latter determined by monitoring changes in vasodilator-activated serum 
phosphoprotein (VASP) phosphorylation (Ser239), were reduced in mice with high Ab42 levels 
(Figure 6, A and B and Figure 7, A and B)).  In contrast, HF-fed BACE1KO mice and DIO mice 
treated with M-3, with reduced levels of Aβ42, exhibit enhanced PKG and p-VASP expression 
levels (Figure 6A and B and Figure 7A and B).  In addition, the intracellular adhesion molecule 
1 (ICAM1) a marker of inflammation and endothelial cell activation, was shown to be increased 
in DIO mice (Figure 6A and B) and in all situations (hAPPSw mice and Ab42 infused mice) where 
Ab42 levels are raised (Figure 6A and B and Figure 7A and B). In contrast, in HF-fed mice 
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where Ab42 is low (HF-fed BACE1KO mice and DIO mice treated with M-3) ICAM1 levels are 
significantly decreased (Figure 6A and B and Figure 7A and B). 
 
Blood pressure. 
We also determined whether the impairments in vascular reactivity induced by raised plasma 
Ab42 also result in changes in blood pressure in mice. Although blood pressure studies on 
conscious mice are preferred, mice with infusion pumps were anesthetised for this 
measurement, resulting in depressed arterial pressure (36). BACE1KO mice are normotensive 
on a RC diet, however loss of BACE1 protects the mice against 20 weeks HF diet-induced 
hypertension (Table 1), as well as maintaining a leaner body weight and lower fasted blood 
glucose (Table 1 and (26)). Furthermore, treatment of DIO mice with a BACE1 inhibitor also 
reduced systolic and diastolic blood pressure (Table 2) and lowered fasted blood glucose and 
body weight, as previously reported (30). In contrast, hAPPSw mice on RC-diet displayed 
raised systolic and diastolic blood pressure (Table 1) and direct infusion of Ab42 also resulted 
in increased blood pressure in anesthetised RC- and HF-fed mice vs ScrP controls (Table 2). 
In general, these manipulations had no effect on heart rate, apart from hAPPSw mice, which 
displayed a significantly raised heart rate and the previously recognised chronotropic effect of 
isoflurane (37). Taken together these data show that the adverse effects induced by Aβ42 on 
the vasculature also result in raised systemic blood pressure (but not heart rate), indicating 
the potential use for BACE1 inhibitors to treat obesity/diabetes induced hypertension. 
 
Plasma Ab42 and human endothelial function. 
The T2D (n=220) and control (n=127) groups (Human Study 2) were matched for age 
(65.1±8.2 and 66.0±8.3 years, respectively), mean arterial blood pressure (95.6±10.8 and 
97.0±12.2 mmHg, respectively) and gender (male:female = 142:85 and 75:53, respectively). 
Body mass index was significantly greater in patients with T2D (32.5±5.67 and 28.4±4.3, 
respectively, P=0.001). Duration of diabetes was 11.2 ± 7.4 years. Plasma Aβ42 levels were 
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significantly greater in patients with T2D compared with values in the control group (12.9±4.3 
and 10.8±3.9 pg/ml, P<0.001).  Endothelial function (RHI) showed significant univariate 
associations with HbA1c (r=-0.271, P<0.0001), BMI (r=-0.259, P<0.0001), female gender 
(r=0.159, P=0.003), Aβ42 (r=-0.142, P=0.008), age (r=0.135, P=0.011) and systolic BP 
(r=0.132 P=0.013). In a stepwise linear regression model, entering HbA1c, BMI, gender, Aβ42, 
age and systolic BP, endothelial function showed an independent association with BMI (β=-
0.215, P<0.001), female gender (β=0.211, P<0.0001), systolic BP (β=0.149, P=0.003), HbA1c 
(β=-0.183, P=0.001), and Aβ42 (β=-0.113, P=0.028), indicating the findings in mice may also 
be relevant to human diabetes and vascular disease. 
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Discussion 
Various reports indicate that exogenously applied soluble Ab40 and/or Ab42 mediate vasoactive 
effects, through inducing vasoconstriction and/or attenuating endothelium-dependent 
vasodilation (15, 38).  Furthermore, in vitro studies suggest that the latter outcome may be 
due, in part, by inhibiting NO production through decreased levels of p-eNOS at Ser1177 in 
endothelial cells (19,20,39).  However, the translation of these in vitro findings to the whole-
body animal and human situation is questionable given that high (~µM) concentrations of Ab 
peptides were applied in many of these studies, orders of magnitude above that reported in 
tissue and blood samples from humans and animals under physiological or pathophysiological 
conditions. In the present study, we demonstrate that chronic HF-feeding of mice, causing 
obesity and hyperglycemia, raises BACE1 activity as monitored by changes in sAPPb levels, 
although the levels of this peptide may also be affected by rates of degradation or recycling 
through endosomes, which were not assessed.  Nevertheless, we show that HF-feeding 
increases Ab42 peptide levels, which do not exceed ~2-10 pM in plasma, with no change in 
Ab40 levels.  A similar magnitude of increase in plasma Ab42, and not Ab40, was also observed 
in a small cohort of patients with diabetes and displayed a positive correlation with the level of 
hyperglycemia. The DIO mice in our study exhibited markedly reduced vascular 
responsiveness to ACh, which was mirrored in RC-fed mice by raising the circulating level of 
Ab42 to that observed in plasma of HF-fed mice, directly by Ab42 infusion or indirectly through 
increased BACE1-dependent cleavage of human mutant APP in transgenic mouse models. 
Importantly this effect of raised Ab42 was independent of HF-feeding, obesity and 
hyperglycemia.  In contrast, in mice lacking BACE1 with very low levels of Ab42 there was no 
loss of ACh vasodilator responsiveness. Furthermore, in DIO mice chronically treated with a 
BACE1 inhibitor to lower Ab42 levels, there was almost complete restoration of the ACh 
vasodilator responsiveness accompanied by reduced blood pressure.  These data strongly 
support the notion that raised Ab42 levels result in vascular dysfunction, leading to more 
constricted blood vessels and contributing to a hypertensive state.  In addition, the aortic 
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vessel walls from HF-fed or Ab42 infused mice demonstrated no lipid deposition, similar 
thickness with uniform layers of smooth muscle and intact endothelial cell layer, and no 
significant inflammatory infiltrate.  Consequently, impairment of endothelium-dependent 
vasodilation by elevated plasma Ab42 is measurable before any histological abnormalities are 
detected in the vessel wall. 
Our in vivo mouse study demonstrates that raised levels of Ab42 result in decreased NO 
production, which appears not to be regulated by a change in total eNOS, but by modulation 
of eNOS activity through a reduction in phosphorylation at Ser1177. This is in line with previous 
work showing that acute application of Aβ reduces NO release, inhibits eNOS activity and 
prevents ACh induced phosphorylation of eNOS, at Ser1177, in cerebral vessels (20,39). The 
post-translational modification of eNOS at this site may be mediated by PKB and/or AMPK 
activity, although the finding that raised Ab42 was associated with diminished PKB (as detected 
through p-PKB levels), rather than AMPK (p-AMPK levels) activity indicates this pathway as 
the predominating site of action.  This is supported by a previous in vitro study using cultured 
endothelial cells, which showed that pM levels of soluble Ab inhibits PKB phosphorylation and 
p-eNOS (37), which may occur by Ab interfering with the formation of the activation complex 
of PKB with phosphoinositide-dependent kinase-1 (PDK-1) (40). 
 
In contrast to the apparently direct effects of Ab42 on NO production, production of ET-1 is not 
increased by Aβ42 under RC-fed conditions in mice by direct infusion of WT mice with mouse 
Ab42 or in AD mouse models overexpressing mutant human APP, but is raised by HF diet 
challenge, an action exacerbated by the presence of Aβ42.  This outcome suggests that the 
vascular dysfunction observed in RC-fed mice associated with raised Ab42 and in AD mouse 
models is primarily driven by NO depletion.  ET-1 levels and activity are enhanced, in 
association with raised vasoconstrictor tone, in people with obesity, type 2 diabetes and the 
metabolic syndrome (41). Moreover, hyperglycemia enhances ET-1 expression and release 
in human and rodent endothelial cells (42,43).  Under physiological conditions ET-1 production 
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is tightly controlled, whereby increased production of NO inhibits expression and production 
of ET-1 (44). Thus, raised levels of Ab42, caused by chronic HF-feeding and hyperglycemia or 
by excessive BACE1 cleavage of mutant APP, as in many familial AD cases and numerous 
AD rodent models (e.g. hAPPSw and hAPP23), will directly diminish NO bioavailability and 
indirectly elevate ET-1 levels. Consequently, reducing plasma and tissue Aβ levels should 
have a substantial beneficial effect on obesity- and diabetes-impaired vasoreactivity. In 
agreement with this notion, we show that treating DIO mice with a BACE1 inhibitor reduced 
circulating levels of Aβ42, restored vascular reactivity and decreased blood pressure 
contemporaneously with elevation of NO levels and suppression of ET-1 production.   
 
Therefore, our results strongly suggest that excessive Aβ induces endothelial dysfunction. 
However impaired vasodilator responses in mice with high levels of Aβ42 (i.e. DIO, RC-fed 
hAPPSw, hAPP23 and Aβ42 infused mice) to the NO donor SNP also indicates endothelium-
independent actions of Aβ42. NO induces vascular relaxation by stimulating production of 
cGMP by soluble guanylate cyclase (sGC) resulting in PKG activation and VSMC relaxation. 
The findings that cGMP, PKG and p-VASP levels in mouse aortas are decreased in mice with 
raised levels of Aβ42 and recovered in DIO mice treated with the BACE1 inhibitor supports 
such a direct link. Indeed, it has been reported that Aβ can downregulate the expression of 
sGC in astrocytes, rendering them less sensitive to SNP (45) and that high (µM) Aβ 
suppresses NO-stimulated sGC activity (and lowers cGMP) in porcine smooth muscle cells 
and human Jurkat cells (46). Thus, HF-feeding and hyperglycemia with subsequent raised 
BACE1 activity and Aβ42 levels inhibits vasodilation and promotes vasoconstriction by multiple 
mechanisms, leading to a hypertensive state. In addition, individuals with AD have reduced 
plasma NO levels and elevated asymmetric dimethylarginine (ADMA) a natural inhibitor of NO 
production (47). 
 
Various studies have demonstrated that Aβ40 and/or Aβ42 induces vascular dysfunction and 
there is a lack of clarity as to the species responsible for direct vascular effects. In this study, 
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we find that Aβ42, but not Aβ40, levels were enhanced by chronic high fat feeding, which 
correlates well with endothelial dysfunction suggesting that Aβ42 may be responsible. It is well 
documented that the aggregation state or “aging” of Aβ peptides has a major influence on their 
biological effects. However, most preceding studies applied high concentrations of freshly-
made monomeric human Ab peptides to tissues or cells, thus lessening the opportunity for 
formation of aggregated states. In the present study, we infused monomeric murine Aβ42 
(which is less aggregation prone than human Aβ42) and have not made any assessment of 
endogenous or exogenous Ab aggregation status, although it is likely that over a 4-week 
exposure period at 37˚C in plasma and tissues, a significant proportion of the infused murine 
Aβ42 will no longer be in the monomeric state.  Importantly, mice overexpressing human 
mutant APP isoforms from birth, on a RC diet, exhibit similar changes in endothelial-
dependent and -independent vasodilation indicating that sufficient Ab42 is present in either 
scenario to cause vascular dysfunction, regardless of aggregation status. The source of 
endogenous plasma and peripheral tissue Aβ42 is uncertain.  BACE1 expression and activity 
is highest in brain and Aβ peptides are transported through the blood-brain-barrier (BBB) to 
the plasma, an action potentially exacerbated by BBB damage associated with 
cerebrovascular pathologies.  However, it is increasingly recognised that BACE1, APP and g-
secretase proteins are also expressed in many peripheral tissues, with blood platelets having 
the highest APP expression after brain and are a significant source of plasma Aβ (48). In 
addition, endothelial and vascular smooth muscle cells express APP and various secretases 
responsible for cleavage and may therefore contribute directly to tissue and plasma Ab load 
under physiological and pathophysiological conditions (49,50). 
 
Our findings in mice of an important role for BACE1 and Aβ42 in vascular dysfunction can be 
translated to humans where we show localization of BACE1 protein in endothelial and vascular 
smooth muscle cells in human temporal artery with raised BACE1 transcript levels in internal 
mammary arteries associated with obesity, but not diabetes. We also find an association 
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between elevated plasma Aβ42 in patients with T2D and a positive correlation with glycated 
haemoglobin suggesting Ab42 may be a contributing factor or marker of hyperglycemia.  
Furthermore, raised plasma Ab42 correlates negatively with endothelial function in humans. 
Thus, the obese state may increase BACE1 transcription, whereas diabetes (hyperglycemia) 
and obesity associate with raised BACE1 activity and higher levels of plasma and tissue Ab42 
in humans and mice (30).  These findings open-up avenues for further exploration of the 
possible role of amyloid proteins in development of vascular dysfunction in obesity and T2D 
and the potential of examining BACE1 inhibitor drugs on vascular dysfunction. 
 
In conclusion, we have demonstrated that metabolic disorder in mice and humans, associated 
with obesity and diabetes, results in elevated plasma Aβ42, which is correlated with the 
presence of peripheral endothelial and vascular dysfunction. This raised plasma Aβ42 results 
in diminished NO production and increased ET-1 leading to depression of endothelium-
dependent vasorelaxation and increased vasoconstriction, which in turn drives local tissue 
ischemia and further increased BACE1 activity and Aβ42 levels, creating a vicious cycle 
associated with progressive vascular dysfunction. Future studies are required to determine 
whether human plasma Aβ peptides may be useful measures in a panel of biomarkers for 
early diagnosis of vascular disease more generally, both in the brain (e.g. dementia) and 
periphery (e.g. atherosclerosis, hypertension). Additionally, repurposing BACE1 inhibitors 
currently undergoing clinical trials for AD for moderation of peripheral Aβ levels could be a 
novel therapy for vascular dysfunction induced by metabolic disease. 
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Methods 
Human study populations.  
Study 1: The Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS) 
project was established in 2005 to identify genetic risk factors for diabetes and its 
complications (51). Participants including individuals with and without diabetes are all required 
to complete a lifestyle questionnaire, a baseline clinical examination and provide their 
biological samples. All participants provided broad informed consent for their health 
information from the NHS and biological samples to be anonymously linked to the study for 
future scientific research. The linked health information includes their personal health status, 
their general practice clinic visits, outpatient appointments, prescribing history and hospital 
admissions.  
Study 2: All participants gave informed written consent. Participants in this study were 
recruited as part of the “surrogate markers for micro- and macro-vascular hard endpoints for 
innovative diabetes tools” (SUMMIT) study (IMI grant number 115006; http://www.imi-
summit.eu) from the Scottish Primary Care Research Network, the Scottish Diabetes 
Research Network, Secondary Care Diabetes Clinics and through advertising such as posters 
and leaflets. Details of the SUMMIT study and plasma sampling are described in detail 
elsewhere (52). 
Two groups of participants were included: 
1) Patients with type 2 diabetes (T2D) with or without diagnosed cardiovascular disease. 
2) A control groups of subjects without T2D but matched for gender and age (± 5 years) 
and type of cardiovascular disease complication 
Presence of cardiovascular disease included a medical history of myocardial infarction, 
percutaneous coronary intervention, coronary arterial bypass graft, unstable angina and 
specialist diagnosed cerebrovascular event from Ninewells Hospital, Dundee. 
Assessment of endothelial function in humans. Endothelial function was measured using an 
EndoPat© (Itamar Medical, Caesarea Ind. Park, Israel), as described previously (53).  In brief, 
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the index-fingers or middle fingers were placed in pneumo-electric tubes and arterial pulsatile 
volume changes were recorded continuously from both hands. Following 8 minutes of rest, a 
blood pressure cuff on the upper arm was inflated to 200 mmHg for 5 minutes to induce 
ischemia. On release of the pressure cuff, the subsequent reactive hyperemia and arterial 
dilation mediated was recorded for 10 minutes. The reactive hyperemia index (RHI) was 
calculated and expressed as a ratio of the post-occlusion to pre-occlusion signal amplitudes. 
 
Assessment of human mammary artery transcripts.  
Human studies included 115 prospectively enrolled patients undergoing coronary artery 
bypass graft (CABG) surgery at the John Radcliffe hospital, Oxford University NHS 
Foundation Trust, UK. Exclusion criteria included any active inflammatory, neoplastic, renal or 
hepatic disease. During surgery, segments of internal mammary artery (IMA) were collected, 
transferred to the lab on ice, and snap-frozen at -80oC for subsequent gene expression studies. 
All patients provided written informed consent prior to enrolment. The demographic 
characteristics of the participants are presented in Supplemental Table 1.  IMA samples were 
harvested at the time of CABG and transferred to the lab in oxygenated (95% O2/5% CO2) ice-
cold Krebs Henseleit buffer. There, the vessel lumen was flushed gently with an insulin syringe 
to remove excess blood. Vessels were then separated from the surrounding adventitial and 
adipose tissue under magnification. The same anaesthetics were used in all cases, and each 
sample was always obtained at the same stage of the operation, to limit inter-patient variability. 
IMA samples were finally snap-frozen in TRI reagent (Sigma) and stored at -80oC until used 
for RNA isolation. Total RNA was isolated by phenol:chloroform (1:5 ratio) separation followed 
by isopropanol precipitation and 70% ethanol clean-up. RNA concentration and quality 
evaluated spectrophotometrically on NanoDrop ND-1000. RNA was reverse-transcribed to 
cDNA by using SuperScript VILO mastermix (Thermo Fischer Scientific) following the 
Manufacturer’s instructions and extending the cDNA synthesis step to two hours at 60oC on a 
Veriti thermal cycler (ABI). Quantitative real-time PCR was performed by TaqMan chemistry, 
using the standard universal TaqMan protocol as indicated by the Manufacturer, on a 
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QuantStudio 7 flex real-time PCR system (Thermo Fischer Scientific). All samples were run in 
duplicate using 5 ng of cDNA as starting mass. A number of standard dilutions of a pooled 
vascular cDNA sample were run on the same plate as the experimental samples in order to 
calculate the efficiency of the probes used; data analysis was then performed by the Pfaffl 
method. GAPDH was used as housekeeping gene for human vascular tissue The IDs of the 
TaqMan probes used are: GAPDH: Hs02786624_g1; BACE1: Hs01121195_m1. 
 
Mouse studies.  
Mice were given free access to food and water and maintained on a 12hr light/dark cycle. 
Male hemizygote B6.129-Tg(APPSw)40Btla/Mmjax (Jax#34831; Transgenic (Tg) mice 
expressing human APP containing the familial AD Swedish double mutation K670N/M671L; 
hAPPSw) or male hemizygote B6.Cg-Tg(Thy1-APP)3Somm/J	 (Jax#030504; Tg mice 
expressing human APP with the Swedish double mutation under the Thy1 promoter; hAPP23) 
were obtained from Jackson Laboratories (29,32). Male and female BACE1 transgenic mice 
on the C57BL/6J background (backcrossed >10 times) provided BACE1 knock-out (BACE1KO) 
mice and WT control littermates (26). For dietary studies, mice were fed regular chow (RC: 
4% calories from fat: RMI 505) throughout the duration of study or at 8-10 weeks old were 
switched to a high fat (HF; 45% calories from fat: SDS 824053) diet (See Supplemental Table 
2 for further details of composition) for the remainder of the study (i.e. 5 weeks or 20 weeks 
(referred to as diet-induced obese (DIO) HF feeding)). Only males were used in the APP, M-
3 and Ab studies. However, both male and female mice were used in the BACE1KO studies, 
with roughly equal % of each sex in each group. Osmotic minipumps (2004 model, Alzet) were 
implanted under inhaled isoflurane anesthesia (1l/min)) and delivered the BACE1 inhibitor M-
3 (10 mg/kg/day) (54) or vehicle (50:50 DMSO:phosphate buffered saline (PBS)) 
subcutaneously (s.c.) for 28 days into WT mice fed a HF diet for 20 weeks (DIO mice).  Aβ42 
or scrambled peptide (ScrP; 3.36 μg/kg) was infused s.c. for 28 days via an osmotic minipump 
into 12-week-old WT mice on RC diet or WT mice fed a HF diet for 1 week prior to surgery. 
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These latter mice, along with hAPPSw and hAPP23 mouse groups, had their microvascular 
function determined at ~16 weeks of age. 
 
Assessment of microvascular function in mice.  
Two days prior to the measurements, hair was removed from the flank area of the mouse 
using a combination of shaving and commercially available depilatory cream (Nair). For 
microvascular assessments, mice were anesthetized (Isoflurane, Abbott Laboratories) and 
body temperature was maintained at 37oC using a heat mat prior to iontophoresis of 
phenylephrine (PE), acetylcholine (ACh) or sodium nitroprusside (SNP). A laser Doppler 
imager (LDI, Moor Instruments, Axminster, UK) was used to measure skin microvascular 
perfusion non-invasively. The LDI performs scans continuously during the iontophoresis 
period and provides a measure of microvascular blood perfusion (in arbitrary perfusion units 
(AU)) as a function of the number of red blood cells multiplied by their mean velocity. Color-
coded images are generated for each perfusion scan and numerical outputs are produced 
using proprietary software (moorLDI software, version 5.3, Moor Instruments). An 
iontophoresis chamber (ION6 probe, Moor Instruments), consisting of a 20mm internal 
diameter ring with a wire electrode running around the inner surface, was attached to the flank 
using double-sided adhesive tape. A ‘reference’ electrode pad was attached to the underside 
of the animal to complete the iontophoresis circuit. To standardize baseline perfusion, blood 
vessels were pre-constricted with iontophoresis of 1% phenylephrine (PE) for 5 minutes 
(current=100μA), followed by iontophoresis of 2% ACh (endothelium-dependent) for 10 
minutes (current=100μA). At a different site on the opposite flank, 2% sodium nitroprusside 
(SNP) (endothelium-independent) was delivered by iontophoresis for 10 minutes 
(current=100μA). To determine the contribution of endothelium-derived NO to ACh-mediated 
vasodilatation, microvascular responses to ACh were assessed after pre-treatment with the 
non-selective inhibitor of NO synthase, N (G)-nitro-L-arginine methyl ester hydrochloride (L-
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NAME, Sigma). L-NAME (20mg/kg) was administered i.p. 30 minutes prior to assessment of 
ACh-mediated vasodilatation (52).  
 
To determine the maximum microvascular dilator capacity, a hyperemic response was initiated, 
on a separate occasion, by localized heating of the skin to 42oC using a specially designed 
heating probe (SH02™ Skin Heating Unit and SHP3 probe, Moor Instruments). Animals were 
anesthetized as described above and a skin heating probe with an internal diameter of 20mm 
and an inner ring heating electrode providing a total surface area of 3.2cm2 was attached to 
the flank using double sided adhesive rings (IAD, Moor Instruments). Baseline measurements 
of perfusion were taken for 5 minutes using LDI, followed by continual assessment of 
microvascular responses to localized heating of the skin as the temperature within the heating 
chamber was increased at a rate of 1oC/min until a maximum temperature of 44oC was 
achieved. This was maintained for a period of >10 minutes which was sufficient to induce a 
plateaued maximum vasodilatation in the skin microcirculation. Perfusion images were 
analyzed using propriety software (Moor Instruments, Version 5.3) and are expressed as a % 
delta response, which was calculated as [maximum vasodilation in response to ACh (or SNP) 
– maximum vasoconstriction in response to PE (i.e a baseline arbitrarily set to 100%)]. For 
localized heating, data are expressed as % change from baseline perfusion at 25-30˚C.  
 
Blood pressure. 
Blood pressure and heart rate were assessed at the terminal time point using the CODA non-
invasive blood pressure system (Kent Scientific, USA). This system consists of an occlusion 
cuff and a volume pressure-recording (VPR) cuff placed around the tail of the animal. Mice 
that underwent minipump implantation had blood pressure measurements made under 
anesthesia.  
 
Protein expression and BACE1 activity.  
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Aortas were dissected, cleaned, washed in ice cold PBS and snap frozen in liquid nitrogen. 
Tissue was homogenized using a probe sonicator (Soniprep 150, MSE) in lysis buffer (26). 
For immunoblotting, 20 μg aortic lysate was separated by SDS-PAGE and transferred to 
nitrocellulose membranes. The details of all primary antibodies used for 
immunohistochemistry (IHC), immunofluorescence (IF) or immunoblot (IB), suppliers, species 
and dilution are shown in Supplemental Table 3. BACE1 activity was determined, indirectly, 
by measuring plasma and tissue levels of the shed soluble product of APP cleavage, sAPPb. 
 
Immunohistochemistry.  
Thoracic aorta was directed and cleaned of perivascular fat before fixation in neutral buffered 
10% formalin for 48 hours. Tissues were embedded in paraffin before 4 µM 
thickness sectioning produced using a microtome (Leica).  Formalin fixed paraffin 
embedded human temporal artery sections were provided by Tayside Biorepository from the 
Tayside pathology archive. Mouse and human sections were stained for BACE1 (1:3000, 
N1C1, GeneTex). For immunofluorescence studies, mice were perfused with PBS followed by 
formalin. Aortas were dissected and cleaned of adventitial tissue and stored in 10% formal 
saline. Aortas were paraffin embedded and sectioned at 14 μm. Sections were baked at 60oC 
for two hours, before dewaxing. Antigen retrieval was performed using trisodium citrate buffer, 
pH 6 and placed in pressure cooker for antigen retrieval. Sections were permeabilised in PBS 
+ 0.5% Triton X100 for 10 minutes, then blocked for 1 hour (PBS + 0.2% BSA+ 10% normal 
Goat serum. Following a PBS wash sections were incubated with primary antibodies (BACE1, 
smooth muscle actin (SMA) or CD31) diluted in PBS + 0.2% BSA for 1 hour RT. Following 
removal of primary antibodies sections were washed 3 x 5 mins in PBS before incubation with 
secondary antibodies (Alexa 488 Goat anti-mouse; Alexa 594 Goat anti-rabbit; 1 in 500: 
Thermofisher) + Hoescht 1ug/ml for 1 hour at RT. Following removal of secondary antibodies, 
sections were washed 3 x 5 mins in PBS before mounting with Vectashield H1000, seal 
coverslips with nail polish and stored at 4 oC until imaged. 
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Analysis of aortic structure. 
Mice were terminally anesthetised and perfusion-fixed with 4% paraformaldehyde in PBS (pH 
7.2) (ThermoFisher Scientific).  Entire aortic trees were harvested and stored for up to 7 days 
in 4% PFA solution to ensure complete fixation. The aortic arch was removed and dissected 
free of fat and other tissue and stained with Oil Red O (Sigma-Aldrich). Stained aortas were 
twice washed in 60% isopropanol, opened, and mounted en face before being imaged digitally 
using an Olympus SZ61 dissecting microscope (magnification: 12x; Olympus Corporation) 
and QImaging QICAM Fast 1394 camera (Teledyne QImaging). Lipid burden was quantified 
from these images using Image-Pro Plus 6.0 software (Media Cybernetics, USA).  The peri-
renal section of the aorta was embedded in Optimal Cutting Temperature compound (VWR 
International, USA) and 10-micron sections produced using a cryostat (Leica Biosystems, 
Germany). Sections were stained for vascular smooth muscle cells using a rabbit anti-a-
smooth muscle actin primary antibody and a goat anti-rabbit Alexa Fluor 647 secondary 
antibody (A21246, 1:200; ThermoFisher Scientific). Sections were co-stained with Isolectin-
B4 conjugated to Alexa Fluor 488 (I21411, 1:100; ThermoFisher Scientific) as an endothelial 
and macrophage marker. Slides were then mounted using DAPI Fluoromount-GÒ mounting 
medium (0100-20; Southern Biotech). Imaging was performed using a Zeiss LSM880 confocal 
microscope with ZEN Black Software (Zeiss) and images analysed using ImageJ open source 
software (NIH - National Institutes of Health). 
 
Aβ and sAPPβ measurement.  
Aβ40, Aβ42 and sAPPβ were measured in mouse plasma and aortic lysate by ELISA as per 
manufacturers’ instructions (MesoScaleDiscovery). Human plasma Aβ40 and Aβ42 in T2D 
patients and controls (Study 1: GoDARTS samples) were measured by ELISA (WAKO), with 
the operator blinded to group membership, performed before obtaining the Simoa platform. 
The Ab42 samples were measured after an 8-fold dilution with an inter assay variation of 1.49% 
and a LLOQ of 0.1pg/ml.  Human plasma Aβ42 (Study 2: SUMMIT samples) was determined 
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in duplicate from each sample using the Simoa HD-1 analyzer (Quanterix; Lexington USA) by 
the University of Dundee immunoassay core facility staff, who were blinded to group 
membership, using a human Aβ42 assay kit (Simoa Human Ab42). The Ab42 samples were 
measured after a 4-fold dilution with an inter assay variation of 5.4% and a LLOQ of 
0.137pg/ml.  
 
Blood chemistry.  
Plasma total NO (NOx) concentration was determined using a total NO assay kit (Enzo Life 
Sciences). Plasma samples underwent ultrafiltration through a 10,000 MWCO filter (Merck 
Millipore) prior to quantification. Endothelin-1 (ET-1) levels were measured by ELISA (R&D 
Systems). Cyclic GMP levels were measured in aortic lysates by ELISA (Cayman chemical) 
following purification with 6% trichloroacetic acid and acetylation using 4M potassium 
hydroxide. Blood glucose was measured in overnight fasted mice using a glucometer (Bayer). 
 
Statistical Analysis.  
Data sets were analysed for statistical significance using GraphPad Prism 6 (GraphPad 
Software Inc, San Diego). Sample size was determined according to our previous studies and 
published reports describing similar experimental procedures.  For mouse studies, the 
investigators were not blinded to treatment groups. All vascular studies and subsequent 
analysis on patients were carried out by operators who were blinded to the status of the 
individual with respect to presence of diabetes or cardiovascular disease. Values are shown 
as means ± SEM, except for results from the SUMMIT study which are presented as means 
± SD. Significance (P ≤ 0.05) was determined by unpaired Student’s t-test, when two groups 
were compared. When three or more groups were compared two-way ANOVA (Tukey’s 
multiple comparison post-test) examined the main factors of diet and genotype for an 
interaction.  All data were tested for normality using the Shapiro-Wilk normality test. All data, 
apart from densitometry analysis of immunoblots, passed this test (P>0.05). Consequently, 
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the immunoblot data were analysed for two or multiple groups using Mann-Whitney and 
Kruskal-Wallis tests, respectively. All normally distributed data sets containing n>6 were 
tested for outliers using the Grubbs test. The association between endothelial function in the 
human study and Ab42 and other parameters was assessed using linear regression. 
 
Study Approval.  
All animal care, experimental protocols and procedures performed in accordance to the 
Animal Scientific Procedures Act (1986), with approval of University of Dundee Ethics 
Committee. For human studies 1 and 2, research conformed to the declaration of Helsinki and 
was approved by Tayside Committee on Medical Research Ethics (REC reference 053/04) 
and the East of Scotland Research Ethics Service (Tayside Committee; 10/S1402/44), 
respectively. For IMA samples, the study protocols agreed with the Declaration of Helsinki 
principles and were approved by the local Research Ethics Committee (Oxford REC 
11/SC/0140). Ethical approval for human temporal artery samples was obtained through 
Tayside Biorepository (TR382).  
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Soluble Guanylyl Cyclase Expression in Astroglial Cells. Neurobiol Dis. 2002;10:139–
149.  
46.  Miller TW, Isenberg JS, Shih HB, Wang Y, Roberts DD. Amyloid-b inhibits No-cGMP 
signaling in a CD36- and CD47-dependent manner. PLoS One. 2010;5:1–10.  
47.  Selley ML. Increased concentrations of homocysteine and asymmetric 
dimethylarginine and decreased concentrations of nitric oxide in the plasma of 
patients with Alzheimer’s disease. Neurobiol Aging. 2003;24:903–907.  
48.  Li Q, Whyte S, Tanner J, Evin G, Beyreuther K, Masters C. Secretion of Alzheimer’s 
disease Abeta amyloid peptide by activated human platelets. Lab Investig. 
1998;78:461–469.  
  36 
49.  Kitazume S, Yoshihisa A, Yamaki T, Oikawa M, Tachida Y, Ogawa K, Imamaki R, 
Takeishi Y, Yamamoto N, Taniguchi N. Soluble amyloid precursor protein 770 is a 
novel biomarker candidate for acute coronary syndrome. Proteomics Clin Appl. 
2013;7:657–663.  
50.  Coma M, Guix FX, Ill-Raga G, Uribesalgo I, Alameda F, Valverde MA, Muñoz FJ. 
Oxidative stress triggers the amyloidogenic pathway in human vascular smooth 
muscle cells. Neurobiol Aging. 2008;29:969–80.  
51. Hébert HL, Shepherd B, Milburn K, Veluchamy A, Meng W, Carr F, Donnelly LA, 
Tavendale R, Leese G, Colhoun HM, Dow E, Morris AD, Doney AS, Lang CC, 
Pearson ER, Smith BH, Palmer CNA. Cohort Profile: Genetics of Diabetes Audit and 
Research in Tayside Scotland (GoDARTS). Int J Epidemiol 2018;47:380-381. 
52.  Shore AC, Colhoun HM, Natali A, Palombo C, Östling G, Aizawa K, Kennbäck C, 
Casanova F, Persson M, Gooding K, Gates PE, Khan F, Looker HC, Adams F, Belch 
J, Pinnoli S, Venturi E, Morizzo C, Goncalves I, Ladenvall C, Nilsson J. Measures of 
atherosclerotic burden are associated with clinically manifest cardiovascular disease 
in type 2 diabetes: A European cross-sectional study. J Intern Med. 2015;278:291–
302.  
53.  Belch JJF, Akbar N, Alapati V, Petrie J, Arthur S, Khan F. Longitudinal assessment of 
endothelial function in the microvasculature of mice in-vivo. Microvasc Res. 
2013;85:86–92.  
54.  Stachel SJ, Coburn CA, Steele TG, Jones KG, Loutzenhiser EF, Gregro AR, 
Rajapakse HA, Lai M-T, Crouthamel M-C, Xu M, Tugusheva K, Lineberger JE, Pietrak 
BL, Espeseth AS, Shi X-P, Chen-Dodson E, Holloway MK, Munshi S, Simon AJ, Kuo 
L, Vacca JP. Structure-Based Design of Potent and Selective Cell-Permeable 
Inhibitors of Human β-Secretase (BACE-1). J Med Chem. 2004;47:6447–6450.  
 
 
 
  37 
Figure 1. BACE1 vascular expression and activity and plasma levels of Ab in mice and 
humans 
(A) Immunohistochemical staining for BACE1 (brown) showing representative sections from 
aortas of RC-fed and HF-fed (DIO) WT mice. (B) Confocal images of DIO mouse aortas (bars: 
50µM) stained for BACE1 (green) and SMA (left) or CD31 (right), respectively (red).  (C) 
Immunohistochemical staining for BACE1 in human non-atherosclerotic temporal artery, with 
a section (rectangle) at higher magnification. (D) BACE1 mRNA expression in internal 
mammary arteries from lean and obese individuals (Mann-Whitney U-test). HF-feeding 
increases BACE1 activity in WT mouse aorta, as determined by sAPPb (E) and Aβ42 (F) levels, 
with BACE1KO aortas showing negligible peptide levels (n=4-12). (G) Plasma Ab42 levels are 
raised in DIO mice to RC-fed hAPPSw mouse levels, with insignificant plasma Ab42 in RC- or 
HF-fed BACE1KO mice (n=6-14). (H) Plasma Ab40 levels of RC- fed and DIO mice and RC- 
and HF-fed BACE1KO mice (n=6-14). (I) Plasma Ab42 and Ab40 levels in control (n=20) and 
obese individuals with Type 2 diabetes (T2D) (n=20).  (J) Linear regression between plasma 
Ab42 and HbA1c in control and obese individuals with T2Ds (P<0.001).  Data presented as 
means ± SEM for all figures except (D) where SD given. * P < 0.05, ** P < 0.01, ***P < 0.001 
by two-way ANOVA with Tukey’s multiple comparisons test (E – H) or 2-tailed unpaired 
Student’s t-test (G(#), I). 
 
 
Figure 2. Loss of BACE1 prevents HF-feeding induced endothelial and vascular smooth 
muscle dysfunction.  
(A) Endothelium-dependent microvascular responses induced by ACh in RC-WT, DIO (20 
week HF-fed) mice and RC- and HF-fed BACE1KO mice (n=10-21). (B) Quantitative analysis 
of ACh response from (A). (C) Endothelium-independent responses induced by SNP in RC-
WT, DIO and BACE1KO mice (n=8-9). (D) Quantitative analysis of SNP responses from (C). 
(E) Microvascular responses induced by ACh in the presence of L-NAME in RC-WT, DIO and 
RC- and HF-fed WT and BACE1KO mice (n=6-10). (F) Quantitative analysis of ACh responses 
from (E). The broken line denotes the RC-fed WT ACh response.  (G) Microvascular 
responses to localised heating in RC-WT, DIO and RC- and HF-fed BACE1KO mice (n=9-11). 
(H) Quantitative analysis of heating responses from (G). Data are means ± SEM. * P < 0.05, 
** P < 0.01, ***P < 0.001 by two-way ANOVA with Tukey’s multiple comparisons test. 
 
Figure 3. Increased circulating Ab42 impairs microvascular function.  
(A) Plasma Ab42 levels in HF(5 weeks)-fed and RC-fed WT mice after 4 weeks Ab42 or ScrP 
infusion (n=7-10). (B) Endothelium-dependent microvascular responses induced by ACh in 
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ScrP and Ab42 treated HF(5 weeks)-fed WT mice (n=9). Quantitative analysis of ACh 
responses for ScrP and Ab42 treated mice. The broken line denotes the RC-fed WT ACh 
response. (C) Endothelium-independent responses induced by SNP in ScrP and Ab42 treated 
HF(5 weeks)-fed WT mice (n=8-9). Quantitative analysis of SNP responses for ScrP and Ab42 
treated mice. The broken line denotes the RC-fed WT SNP response. (D) Microvascular 
responses induced by ACh in RC-fed WT and hAPPSw mice and hAPPSw mice with L-NAME 
(L-N) (n=6-16). Quantitative analysis of ACh responses for hAPPSw mice in the absence and 
presence of L-NAME. The broken line denotes the RC-fed WT ACh response. (E) 
Endothelium-independent responses induced by SNP in RC-fed WT and hAPPSw mice (n=5-
8). Quantitative analysis of SNP responses. (F) Endothelium-dependent microvascular 
responses induced by ACh in ScrP and Ab42 treated RC-fed WT mice (n=7-9). Quantitative 
analysis of ACh responses for ScrP and Ab42 treated mice. The broken line denotes the RC-
fed WT ACh response. (G) Endothelium-independent responses induced by SNP in ScrP and 
Ab42 treated RC-fed WT mice (n=7-9). Quantitative analysis of SNP responses for ScrP and 
Ab42 treated mice. The broken line denotes the RC-fed WT SNP response. Data are means ± 
SEM. * P < 0.05, ** P < 0.01, ***P < 0.001 by 2-tailed unpaired Student’s t-test. 
 
Figure 4. M-3 recovers microvascular function in DIO mice and plasma Ab42 correlates 
with microvascular responsiveness. (A) Plasma Ab42 levels of DIO mice treated with M-3  
or vehicle (n=8). (B) Endothelium-dependent microvascular responses induced by ACh in 
vehicle and M-3 treated DIO mice (n=9). Quantitative analysis of ACh responses for vehicle 
and M-3 treated mice. The broken line denotes the RC-fed WT ACh response. (C) 
Endothelium-independent responses induced by SNP in vehicle and M-3 treated DIO mice 
(n=8). Quantitative analysis of SNP responses for vehicle and M-3 treated mice. The broken 
line denotes the RC-fed WT SNP response. Linear regression between plasma Ab42 levels 
and ACh (D) and SNP (E) responses for experimental groups of mice.  Data are means ± 
SEM. ** P < 0.01, ***P < 0.001 by 2-tailed unpaired Student’s t-test. 
 
Figure 5. Plasma NOx, ET-1 and aortic cGMP are modified by BACE1 activity and Ab42.  
(A) Plasma NOx levels in RC-fed WT, hAPPSw and BACE1KO, DIO and HF-fed BACE1KO 
mice (n=9-14). (B) Plasma NOx levels in RC-fed WT and HF(5 weeks)-fed mice after 4 weeks 
Ab42 or ScrP infusion (n=4-12). (C) Plasma NOx levels in vehicle and M-3 treated DIO mice 
(n=12-14). (D) Plasma ET-1 levels in RC-fed WT, hAPPSw and BACE1KO, DIO and HF-fed 
BACE1KO mice (n=9-21). (E) Plasma ET-1 levels in RC-fed WT and HF(5 weeks)-fed mice 
after 4 weeks Ab42 or ScrP infusion (n=4-12). (F) Plasma ET-1 levels in vehicle and M-3 treated 
DIO mice (n=8-18). (G) Aortic cGMP levels in RC-fed WT, hAPPSw and BACE1KO, DIO and 
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HF-fed BACE1KO mice (n=6-12). (H) Aortic cGMP levels in HF(5 weeks)-fed mice after 4 
weeks Ab42 or ScrP infusion (n=9-10) and (I) in vehicle and M-3 treated DIO mice (n=10-11). 
Data are means ± SEM. * P < 0.05, ** P < 0.01, ***P < 0.001 by two-way ANOVA with Tukey’s 
multiple comparisons test (A,B,D,E,G,H) or 2-tailed unpaired Student’s t-test (C,F,I) and # vs 
WT RC (A,G). 
 
Figure 6. Aortic NO signalling is modified in BACE1KO and hAPPSw mice.  
(A) Representative immunoblots of p-eNOS(Ser1177), eNOS, p-PKB(Ser473), PKB, p-
AMPK(Thr172), AMPK, PKG, p-VASP(Ser239), ICAM1 and actin in aortas of RC-fed WT, DIO 
and RC- and HF-fed BACE1KO mice (left panel) and from aortas of RC-fed WT and RC-fed 
hAPPSw mice (right panel). (B) Ratio of signal intensities for p-eNOS to eNOS, p-PKB to PKB, 
p-AMPK to AMPK, p-VASP, PKG and ICAM1 to actin (n=6-15). Data are means ± SEM. * P < 
0.05, ** P < 0.01, *** P < 0.001 by Kruskal-Wallis test with Dunn’s multiple comparisons test; 
# P < 0.05 and ## P < 0.01 by Mann-Whitney test (vs RC WT mice). 
 
Figure 7. BACE1 activity and Ab42 regulate aortic NO signalling.  
(A) Representative immunoblots of p-eNOS(Ser1177), eNOS, p-PKB(Ser473), PKB, p-
AMPK(Thr172), AMPK, PKG, p-VASP(Ser239), ICAM1 and actin in aortas of ScrP and Ab42 
treated RC-fed (left panel) and HF(5 weeks)-fed WT mice (middle panel) and in aortas of 
vehicle or M-3-treated DIO mice (right panel). (B) Ratio of signal intensities for p-eNOS to 
eNOS, p-PKB to PKB, p-AMPK to AMPK, and for PKG, p-VASP and ICAM1 to actin (n=5-14).  
Data are means ± SEM. * P < 0.05, **P < 0.01, ***P < 0.001 by Mann-Whitney test. 
 
 
Supplemental Figure 1.  High fat fed WT mice exhibit increased body weight, impaired 
glucose disposal higher fasted glucose and reduced insulin sensitivity. 
(A) Body weight curves of age-matched (8-10 weeks old) WT littermate mice following 20 
weeks of regular chow (RC: n=11) or high fat (HF: n=15) diet. (B) Intraperitoneal glucose 
tolerance on RC-fed (n=5) and HF-fed (n=12) WT mice performed on week 19 of dietary 
intervention.  (C) Fasted blood glucose levels of WT mice on RC or HF diet for 19 weeks.  (D) 
Intraperitoneal insulin tolerance on RC-fed (n=8) and HF-fed (n=6) WT mice performed on 
week 20 of dietary intervention. Data are means ± SEM. ***P < 0.001 by 2-tailed unpaired 
Student’s t-test. 
 
Supplemental Figure 2. Internal mammary artery BACE1 mRNA expression as a 
function of diabetes and insulin resistance. 
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IR: insulin resistance (defined by HOMA-IR > 2.8).  DM: diabetes mellitus. NS: non-significant. 
Data presented as means ± SD. 
 
Supplemental Figure 3.  ACh response size and plasma Ab42 with time on HF diet. 
(A) Endothelium-dependent microvascular responses induced by ACh in HF-fed WT  
and BACE1KO mice as a function of time on diet (n=6-18). (B)  Endothelium-dependent  
microvascular responses induced by ACh with corresponding plasma Ab42 levels in HF-fed  
untreated WT mice as a function of time on diet (n=9-19). Data are means ± SEM. 
 
Supplemental Figure 4.  M-3 improves microvascular function in hAPP23 mice. 
(A) Endothelium-dependent microvascular responses induced by ACh in RC-fed  
hAPP23 mice (n=4) after 4 weeks infusion of vehicle or M-3, with quantitative analysis  
of ACh response. The broken line denotes the RC-fed BACE1KO ACh response. (B)  
Endothelium-independent responses induced by SNP in RC-fed hAPP23 mice (n=4)  
after 4 weeks infusion of vehicle or M-3, with quantitative analysis of SNP response.  
The broken line denotes the RC-fed BACE1KO SNP response. (C) Plasma NOx levels  
in vehicle and M-3 treated hAPP23 mice (n=3-4). (D) Plasma ET-1 levels in vehicle  
and M-3 treated hAPP23 mice (n=4).  Data are means ± SEM. * P < 0.05 by 1-tailed  
unpaired Student’s t-test. 
 
Supplemental Figure 5. Lack of lipid deposition in aortic arch. 
Representative images of aortic arches stained with Oil Red O. No lipid deposition  
was detected in aortic arch of WT and BACE1KO mice on (A) regular chow or after (B) 
5 weeks or (C) 12 weeks on high fat diet. (D) Infusion of ScrP or Ab42 did not cause  
lipid deposition. 
 
Supplemental Figure 6. Immunohistochemical analysis of aortic wall structure. 
Representative images of peri-renal sections stained with isolectin B4 (Green) and a- 
smooth muscle actin (Red) from WT and BACE1KO mice on (A) regular chow diet 
and (B) 12 weeks on high fat diet or (C) following infusion of ScrP or Ab42. (D) Aortic  
wall thickness is unchanged by these treatments, n = 3. 
 
 
 













 
Table 1 Phenotype characteristics of WT and BACE1KO mice on RC or HF diet, and hAPPSw on RC diet,  
for 20 weeks.  
	
	
	
			
 
 
 
 
 
 
a  P < 0.001, b  P < 0.01, c  P < 0.05 vs WT RC; and d P < 0.01 vs WT HF 
 
Group (n) Body weight (g) Fasted blood 
glucose (mM) 
Systolic blood 
pressure (mm 
Hg) 
Diastolic blood 
pressure (mm 
Hg) 
Heart rate 
(b/min) 
WT RC (18) 33.2 ± 1.0 4.1 ± 0.2 112.5 ± 6.0 83.4 ± 6.0 626 ± 51 
WT HF (16) 43.3 ± 1.8a 7.0 ± 0.3a 137.8 ± 5.2b 113.7 ± 4.7a 609 ± 67 
BACE1KO RC (12) 25.9 ± 1.3b 3.2 ± 0.2c 114.8 ± 8.1 90.8 ± 6.5 612 ± 45 
BACE1KO HF (13) 33.7 ± 1.2d 5.8 ± 0.5d 118.3 ± 6.3d 88.9 ± 6.1d 651 ± 57 
hAPPSw RC (13) 33.3 ± 0.8 3.8 ± 0.2 138.3 ± 7.6c 110.8 ± 6.8b 751 ± 29c 
	
	
 
 
 
 
Table 2. Phenotype characteristics of anesthetized mice infused with Vehicle, M-3, ScrP or Ab42 
 
 
 
 
 
 
 
 
 
 
 
*These mice given HF diet for 20 weeks prior to measurements being taken, all other groups on RC- or HF-diet for 5 weeks. 
a  P < 0.05 vs WT HF + Veh, b  P < 0.01 vs WT HF + Veh, c  P < 0.05 vs RC + ScrP, d  P < 0.05 vs WT HF + ScrP,  
e  P < 0.01 vs WT HF + ScrP 
 
	
Group (n) Body weight (g) 
(pre-infusion) 
Fasted blood 
glucose (mM) 
Systolic blood 
pressure (mm Hg) 
Diastolic blood 
pressure (mm Hg) 
Heart rate 
(b/min) 
D Body weight 
(%) 
*WT HF + Veh (12) 45.1 ± 1.5 6.2 ± 0.5 97.2 ± 2.9 71.7 ± 2.9 263 ± 21 -2.0 ± 0.9 
*WT HF + M-3 (14) 48.1 ± 2.7  5.2 ± 0.2a 82.5 ± 5.2a 60.6 ± 2.1a 233 ± 24 -9.9 ± 2.0b 
 WT RC + ScrP (7) 29.6 ± 1.4 3.6 ± 0.5 94.2 ± 4.8 77.8 ± 6.2 304 ± 35 0.9 ± 1.8 
 WT RC + Ab42 (9) 31.2 ± 1.3 3.1 ± 0.2 113.5 ± 7.1c 95.9 ± 7.9c 314 ± 28 3.9 ± 0.6 
WT HF + ScrP (10) 34.5 ± 1.7 5.5. ± 0.3 94.3 ± 3.1 71.4 ± 4.5 215 ± 38 5.8 ± 3.0 
 WT HF + Ab42 (12) 35.4 ± 1.9 5.8 ± 0.4 117.0 ± 8.5 89.2 ± 2.5d 315 ± 23 16.9 ± 2.1e 
Supplemental Table 1.  
 
Demographic characteristics of participants undergoing CABG surgery. 
 
 Lean Overweight Obese 
N 28 80 7 
Age (years) 68.6 (10.8) 66.3 (9.9) 71.3 (7.2) 
BMI (kg/m2) 22.8 (2.0) 29.9 (2.3) 37.3 (2.6) 
Diabetes (%) 14.3 5.7 42.8 
Insulin (mIU/L) 7.4 (9.7) 10.9 (10.8) 11.1 (10.1) 
Glucose (mg/dL) 97 (30.9) 109 (36.9) 125.7 (39.7) 
HOMA-IR 1.9 (3.5) 2.0 (1.7) 3.6 (3.5) 
 
Values are expressed as means with SD in brackets. 
Supplemental Table 2.  
(A) General composition of regular chow (RC) and high fat (HF) diets and (B) carbohydrate 
and fat composition of diets for mice. 
 
A 
Kcal composition RC 
(RM1) 
HF 
(824053) 
Crude fat (%) 7.4 45 
Crude Protein (%) 17.5 20 
Carbohydrate (%) 75.1 35 
 
 
B 
Carbohydrate/Fat 
composition 
RC HF 
Rice starch (% w/w) 45 28.3 
Mixed sugars (% w/w) 4.5 - 
Soya oil (% w/w) 2.71 4.3 
Sucrose (% w/w) - 10.5 
Lard (% w/w) - 17.9 
 
Supplemental Table 3.  
Source, catalogue number, species and dilution of antibodies used for immunoblots. 
 
Primary Antibody Species Dilution Source 
Bace1 Rabbit 1:500 (IF) 
1:3000 (IHC) 
Genetex 
(GTX113319) 
CD31 Mouse 1:25 (IHC) Abcam 
(ab9498) 
Smooth muscle actin 
(SMA) 
Mouse 1:1000 (IHC) Abcam 
(ab7817) 
Smooth muscle actin 
(SMA) 
Rabbit 1:100 (IHC) Abcam 
(ab5694) 
peNOS  
(Ser1177) 
Mouse 1:1000 (IB) BD Transduction 
(612392) 
eNOS Rabbit 1:1000 (IB) Cell Signalling 
(32027) 
pPKB 
(Ser473) 
Rabbit 1:1000 (IB) Cell Signalling 
(9271) 
PKB Rabbit 1:1000 (IB) Cell Signalling 
(4691) 
pAMPK 
(Thr172) 
Rabbit 1:1000 (IB) Cell Signalling 
(2535) 
AMPK Rabbit 1:1000 (IB) Cell Signalling 
(5832) 
PKG Rabbit 1:1000 (IB) Cell Signalling 
(3248) 
pVASP 
(Ser239) 
Rabbit 1:1000 (IB) Cell Signalling 
(3114) 
ICAM1 Mouse 1:1000 (IB) R&D Systems 
(AF796) 
Actin Rabbit 1:5000 (IB) Sigma Aldrich 
(A2066) 
 
 
 
